Opposing sides continue ICD-10 debate

In the ongoing saga of ICD-10 implementation, opposing sides continue to advocate their positions.

Several state medical associations and the National Physicians' Council for Healthcare Policy sent a letter to House Speaker John Boehner urging a delay of implementation of the new code set by two years.

The Texas Medical Association also calls for a 2017 implementation date, offering up text that providers can copy and paste to appeal for another delay. “It’s imperative that you contact your representative today and explain how you cannot afford the cost and disruption of ICD-10 implementation to your business, especially now, when you are buried in myriad other bureaucratic burdens.”

The organization advises providers to cut and paste its letter onto their personal stationery. The letter says that physicians will be the hardest hit for the costs of implementing ICD-10, spending $356 million and losing $571 million from decreased productivity.  

Last year’s delay was added to legislation for the sustainable growth rate patch but in a recent article, the American Health Information Management Association (AHIMA) said a delay could be attached in an amendment to a $157 billion fiscal 2015 spending bill for the departments of Labor, Education and Health and Human Services that expires on Dec. 11.

Meanwhile, the association issued a statement conveying its ongoing support for an Oct. 1, 2015, implementation date. “The industry has already seen two delays in implementation, and each delay has cost the industry billions of dollars, as well as the untold costs of lost benefits from implementing a more effective code set.”

AHIMA cites surveys that indicate lower implementation costs than initially estimated and good progress among providers in implementation preparations.

“Another delay will only further deter progress and cost the industry money. There is no benefit to deferring implementation,” the group says.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.